NASDAQ: AGMB
Agomab Therapeutics Nv Stock Ownership - Who owns Agomab Therapeutics Nv?

Insider buying vs selling

Have Agomab Therapeutics Nv insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when AGMB insiders and whales buy or sell their stock.

AGMB Shareholders

What type of owners hold Agomab Therapeutics Nv stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Eqt Fund Management Sa Rl10.55%5,141,992$53.12MInstitution
Sanofi5.71%2,783,096$28.75MInstitution
Cormorant Asset Management LP5.06%2,465,348$25.47MInstitution
Tcg Crossover Management LLC4.21%2,053,233$21.21MInstitution
Federated Hermes Inc3.32%1,618,000$16.71MInstitution
Casdin Capital LLC3.18%1,550,000$16.01MInstitution
Andera Partners3.16%1,538,702$15.89MInstitution
Fmr LLC2.99%1,458,677$15.07MInstitution
Nantahala Capital Management LLC2.46%1,200,000$12.40MInstitution
Aberdeen Group PLC1.45%707,656$7.31MInstitution

1 of 3

AGMB vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AGMB47.92%0.09%
KYTX56.77%43.23%Net BuyingNet Selling
CABA51.93%2.67%Net Buying
FDMT79.90%20.10%Net BuyingNet Selling
PROK14.45%39.04%Net Selling

Agomab Therapeutics Nv Stock Ownership FAQ

Who owns Agomab Therapeutics Nv?

Agomab Therapeutics Nv (NASDAQ: AGMB) is owned by 47.92% institutional shareholders, 0.09% Agomab Therapeutics Nv insiders, and 51.99% retail investors. Tim Jasper Knotnerus is the largest individual Agomab Therapeutics Nv shareholder, owning 45,217.00 shares representing 0.09% of the company. Tim Jasper Knotnerus's Agomab Therapeutics Nv shares are currently valued at $446.74k.

If you're new to stock investing, here's how to buy Agomab Therapeutics Nv stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.